What's in Sinovac (Dalian) Vaccine Technology Co., Ltd.'s pipeline?

Sinovac (Dalian) Vaccine Technology Co., Ltd. has 8 drugs in our index: 3 marketed, 0 filed, 3 in Phase 3, 1 in Phase 2, 1 in Phase 1.

Which companies overlap with Sinovac (Dalian) Vaccine Technology Co., Ltd.'s portfolio?

Top competitors by shared drug class: GlaxoSmithKline, Centers for Disease Control and Prevention, Bandim Health Project, Beijing Center for Disease Control and Prevention, Canadian Immunization Research Network.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/sinovac-dalian-vaccine-technology-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Sinovac (Dalian) Vaccine Technology Co., Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sinovac (Dalian) Vaccine Technology Co., Ltd. pipeline: 3 marketed, 0 filed, 3 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 3 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Investigational live attenuated varicella vaccine	Investigational live attenuated varicella vaccine	marketed
Mumps vaccine	Mumps vaccine	marketed	Live attenuated vaccine	Mumps virus surface antigens	Immunology / Infectious Disease
Varicella vaccine+TIV	Varicella vaccine+TIV	marketed	vaccine		Immunology
PROVARIX	PROVARIX	phase 3	Recombinant subunit vaccine	Varicella-zoster virus glycoprotein E (gE)	Immunology / Infectious Disease
Vaccine manufactured at commercialized scale	Vaccine manufactured at commercialized scale	phase 3	vaccine		Immunology
diluent of lyophilized vaccine	diluent of lyophilized vaccine	phase 3

Therapeutic area mix

Immunology · 2
Immunology / Infectious Disease · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 3 shared drug classes
Centers for Disease Control and Prevention · 2 shared drug classes
Bandim Health Project · 2 shared drug classes
Beijing Center for Disease Control and Prevention · 2 shared drug classes
Canadian Immunization Research Network · 2 shared drug classes
Chinese Academy of Medical Sciences · 2 shared drug classes
Aga Khan University · 2 shared drug classes
Institute of Medical Biology, Chinese Academy of Medical Sciences · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Sinovac (Dalian) Vaccine Technology Co., Ltd.:

Cite this brief

Drug Landscape (2026). Sinovac (Dalian) Vaccine Technology Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sinovac-dalian-vaccine-technology-co-ltd. Accessed 2026-05-17.